Biotech · Private company
Eureka Therapeutics Inc.
Track this companyFree. Adds Eureka Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- ECT204 T cellsPhase 2 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ET140203 T CellsPhase 2 · HepatoblastomaClinicalTrials.gov · fetched Nov 12, 2026
- ET140202 autologous T cell productPhase 1 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ET140203 autologous T cell productPhase 1 · Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ET190L1 ARTEMIS™ T cellsPhase 1 · Lymphomas Non-Hodgkin's B-CellClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)PHASE1_PHASE2 · RECRUITING · started Jun 1, 2024ClinicalTrials.gov NCT06343311 · fetched Nov 12, 2026
- ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular CarcinomaPHASE1_PHASE2 · RECRUITING · started Jul 19, 2022ClinicalTrials.gov NCT04634357 · fetched Nov 12, 2026
- GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCCPHASE1_PHASE2 · RECRUITING · started Mar 11, 2022ClinicalTrials.gov NCT04864054 · fetched Nov 12, 2026
- Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)PHASE1 · TERMINATED · started Apr 14, 2021ClinicalTrials.gov NCT04502082 · fetched Nov 12, 2026
- Study of ET140202 T Cells in Adults With Advanced Hepatocellular CarcinomaPHASE1 · TERMINATED · started May 30, 2019ClinicalTrials.gov NCT03998033 · fetched Nov 12, 2026
- Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's LymphomaPHASE1 · TERMINATED · started Apr 4, 2018ClinicalTrials.gov NCT03379493 · fetched Nov 12, 2026